Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (2018)
15 slides from Coloplast A/s Class B's investor day presentation, 2018
Slide 1: Group Strategy update
Group Strategy update Coloplast Capital Markets Day 2018 Lars Rasmussen, President & CEO
Slide 2: We changed our long term guidance to invest in more growth
We changed our long term guidance to invest in more growth and are satisfied with 5 quarters of 8% organic growth Long Term Guidance Organic growth in percentage 17/18-19/20 Full year Quarter Organic Revenue Growth 8 8 8 8 8 7 7 7 7-9% 4-5% market growth EBIT %, fixed currencies >30% FY 14/15 FY 15/
Slide 3: We continue to gain market share across our business areas
We continue to gain market share across our business areas Market share development Percentage point increase from 16/17 to 9M 17/18 +1% +1% +0% +1% Market share 35-40% ~40% 7-9% ~15% Market position #1 #1 #5 #4 Source: Coloplast estimates • . Page 3
Slide 4: Since the launch of LEAD20 we have invested significantly to fuel future growth
Since the launch of LEAD20 we have invested significantly to fuel future growth and sustain market share gains Investment overview Investment allocation by type Traditional investment areas FY 15/16 to 9M 17/18 Incremental Sales force Consumer/DTC R&D Up to 2% of revenues in incremental investments
Slide 5: To fuel growth, two key investment areas will be Emerging markets and US
To fuel growth short to mid-term, two key investment areas will be Emerging markets and US In Emerging markets, we invest to deliver 15-20% growth … while we in the US invest to deliver +10% growth and by leveraging our proven commercial model … build a new service model Sales force expansion is a k
Slide 6: Today we will focus on our Innovation and User focused efforts
Today we will focus on our Innovation and User focused efforts 1 2 Understanding users’ lives in full Creating Fighting life-changing for products and better care services Supporting beyond expectations Page 6
Slide 7: With SenSura Mio Concave we have completed our ostomy product portfolio
1 SUPERIOR PRODUCTS AND INNOVATION With SenSura® Mio Concave we have completed our ostomy product portfolio and now address all body shapes With SenSura® Mio Concave we are building a new innovative product category that addresses an unmet need Innovation supported by clinical trials with a 30% mark
Slide 8: We have a strong catheter portfolio and continue to focus on UTIs
1 SUPERIOR PRODUCTS AND INNOVATION We have a strong catheter portfolio and continue to focus on solving the key clinical challenge of UTIs The catheter portfolio is strong, but users are still troubled by UTIs Our Bacteria Barrier Technology is a first step towards 2 addressing this challenge 1) Col
Slide 9: We are committed to Wound Care and are investing in innovation
1 SUPERIOR PRODUCTS AND INNOVATION We are committed to Wound Care and are investing in innovation and commercial initiatives to scale the business We see attractive value creation opportunities within the Wound Care market The Biatain® Silicone portfolio and 3DFit® Technology are driving growth in t
Slide 10: Urology Care has delivered on the strategy set out in 2014
1 SUPERIOR PRODUCTS AND INNOVATION Urology Care has delivered on the strategy set out in 2014 and is a ~DKK 2bn business with improved profitability Urology Care has delivered on their current strategy and is now a more profitable ~DKK 2bn business Today, Urology Care will share their new strategy a
Slide 11: We now reach out to more than 1 million consumers
2 UNIQUE USER FOCUSED MARKET APPROACH We now reach out to more than 1 million consumers making Coloplast a true consumer healthcare company Through our Coloplast Care program and DtC initiatives, we now have more than 1 million consumers in our database across more than 30 countries The Coloplast Ca
Slide 12: Superior products, Coloplast Care and direct distribution form a strong commercial model
2 UNIQUE USER FOCUSED MARKET APPROACH The combination of superior products, Coloplast Care and direct distribution is a strong commercial model We have a strong commercial model with products, services and direct distribution With our recent acquisitions we are now fully capable in five key markets
Slide 13: Digitalization is a focus area across products, services and distribution
To further strengthen the commercial model, digitalization is a focus area across products, services and distribution Digitalization plays a significant role in the development of Coloplast Products: Digitalized products are key to next Products Services Distribution level innovation Services: Colop
Slide 14: Through digitalization of new products, we take the next step towards our mission
Through digitalization of new products, we will take the next step towards our mission of making life easier for our users Digitalization in product development as first important milestone Digitalization • We have a mission of making life easier for people with intimate healthcare needs • Digitaliz
Slide 15: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C